标题 |
[高分] Dalpiciclib versus placebo in combination with letrozole or anastrozole asfirst-line treatment for women with HR+/HER2- advanced breast cancer:prespecified final analysis of progression-free survival of the phase 3 DAWNA-2trial
Dalpiciclib与安慰剂联合来曲唑或阿那曲唑作为HR+/HER2-晚期乳腺癌女性一线治疗的比较:3期DAWNA-2试验无进展生存期的预先指定最终分析
|
备注 |
我要徐兵河教授在2024年SABCS上的壁报或者汇报PPT,不要摘要
|
网址 |
求助人暂未提供
|
DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
其它 |
2024 SABCS PS2-01: Dalpiciclib versus placebo in combination with letrozole or anastrozole asfirst-line treatment for women with HR+/HER2- advanced breast cancer:prespecified final analysis of progression-free survival of the phase 3 DAWNA-2trial. Binghe Xu, Cancer Hospital, Chinese Academy of Medical Sciences, Being, China |
求助人 | |
下载 |